Normal view MARC view ISBD view

The Orsiro ultrathin, bioresorbable-polymer sirolimus-eluting stent: A review of current evidence. [Review] - 2020

Available in print through MWHC library: 2002 - present

Advances in stent design and the development of bioresorbable polymers have allowed the development of novel stent technologies such as the Orsiro bioresorbable-polymer sirolimus eluting stent (BP-SES). Over several noninferiority trials, the BP-SES has demonstrated itself to be a safe and effective therapy for obstructive coronary artery disease. This article reviews the current evidence of the efficacy of the BP-SES and examines its performance in high-risk populations, such as patients presenting with ST-segment myocardial infarction, chronic total occlusions, diabetes, and small vessel disease. Copyright (c) 2020 Elsevier Inc. All rights reserved.


English

ISSN: 1878-0938

Standard No.: 10.1016/j.carrev.2019.12.039 [doi] S1553-8389(20)30009-9 [pii]

Subjects--Topical Terms:
*Absorbable Implants
*Acute Coronary Syndrome/th [Therapy]
*Cardiovascular Agents/ad [Administration & Dosage]
*Coronary Artery Disease/th [Therapy]
*Drug-Eluting Stents
*Percutaneous Coronary Intervention/is [Instrumentation]
*Sirolimus/ad [Administration & Dosage]
Acute Coronary Syndrome/dg [Diagnostic Imaging]
Cardiovascular Agents/ae [Adverse Effects]
Coronary Artery Disease/dg [Diagnostic Imaging]
Humans
Percutaneous Coronary Intervention/ae [Adverse Effects]
Prosthesis Design
Risk Factors
Sirolimus/ae [Adverse Effects]
Time Factors
Treatment Outcome

Subjects--Geographic Terms:
MedStar Heart & Vascular Instituteon

Index Terms--Function:
Journal Article
Review